Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of IL-YANG Inactivated Split Influenza Vaccine in Healthy Korean Males
NCT02111070Phase 1Completed
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Sep 2012
- Primary completion
- Oct 2012
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Ilyang Flu Vaccine in influenza, sponsored by Il-Yang Pharmaceutical. Primary endpoints: Solicited local & general AE, Unsolicited AE at Day 28 and Percentage of subjects achieving seroprotection for HI antibody at Day 28. Started Sep 2012; status: completed.
02
Drugs
Ilyang Flu Vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02111070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02111070.